AMOEBA (EPA:ALMIB) - AMOEBA PUBLISHES A NEW SCIENTIFIC ARTICLE IN THE MICROORGANISMS JOURNAL

Transparency directive : regulatory news

22/05/2020 08:00

PRESS RELEASE

AMOEBA PUBLISHES A NEW SCIENTIFIC ARTICLE IN THE MICROORGANISMS JOURNAL

Chassieu (France), may 22, 2020 - AMOÉBA (FR0011051598 - AMEBA), producer of a
biological biocide, capable of eliminating bacterial risk in water and human
wounds, and a biocontrol product for plant protection, still in the testing
phase, announces the publication of a major new scientific paper
(https://www.mdpi.com/2076-2607/8/5/771/pdf). This work, carried out jointly by
the Institut Hospitalo-Universitaire Méditerranée Infection in Marseille and
Amoéba in Chassieu, has been published in the biotechnology section of
"Microorganisms", an international peer-reviewed scientific journal.

As scientific knowledge on non-pathogenic amoebae is limited, the sequencing
of the genome of the Willaertia magna C2c maky amoeba published in 2019 (DOI:
10.1038/s41598-019-54580-6) allowed to know the genetic potential(1) of the
amoeba. The analysis focused this time on the transcriptome(2) and the
proteome(3) of this amoeba when grown at high throughput in a bioreactor in
order to complete our knowledge by identifying the actually expressed genes
during the amoeba production. This work provides essential elements on the
development and metabolism of the industrially produced amoeba by the Company.

The study confirms two major discoveries that had been suggested with the
analysis of the Willaertia magna C2c maky genome. First, the amoeba does
produce a wide range of enzymes involved in the metabolism of secondary
metabolites with antimicrobial activity and proteins associated with defense
mechanisms against other microorganisms. Secondly, these molecules are well
expressed under the particular conditions of bioreactor production.

These results support the efficacy of this amoeba as a natural biocide in
cooling tower water and as a biocontrol agent as an alternative to pesticides
in agriculture.

Finally, an in-depth analysis of the energy metabolism provides leads for the
optimization of the cultivation conditions and thus the production yield of the
amoeba.

"This paper confirms the data acquired on the genome of Willaertia magna C2c
Maky and begins to address the understanding of the mechanism of its
microbicidal action. The next steps will consist in studying the non-protein
products generated by this amoeba while testing certain hypotheses for
improvement in terms of optimizing its industrial production", says Professor
Bernard LA SCOLA, head of the team behind these results at IHU Méditerranée
Infection.

"This article is the 3rd published in less than one year. It confirms our
strategy of marketing Willaertia magna C2c maky as a biocidal and biocontrol
agent. We are continuing our R&D operations, the results of which will also
be the subject of new publications. "says Sandrine DEMANECHE, scientific
manager of Amoéba.

(1) Not all the genes present in the genome are permanently expressed, some are
induced depending on the conditions encountered
(2) Set of ribonucleic acids (RNA) resulting from the transcription of the
genome. The characterization of the transcriptome makes it possible to identify
the genes that are active under given conditions.
(3) Set of proteins produced under given conditions

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20- (a copy of which is available on www.amoeba-biocide.com). The forward-
looking statements contained in this press release are also subject to risks
not yet known to AMOEBA or not currently considered material by AMOEBA. The
occurrence of all or part of such risks could cause actual results, financial
conditions, performance or achievements of AMOEBA to be materially different
from such forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA PUBLISHES A NEW SCIENTIFIC ARTICLE IN THE MICROORGANISMS JOURNAL

Transparency directive : regulatory news

AMOEBA's latest news

Other stories